LILIA FRAUSTO: Open Payments
NPI 1518151984 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$723 in 15 payments from 10 companies in 2025. Trend: 2023 $237 · 2024 $414 · 2025 $723
Food & beverage: $723
| Company | Payments | Amount |
|---|---|---|
| Incyte Corporation | 3 | $150 |
| Astellas Pharma US Inc | 1 | $126 |
| Syndax Pharmaceuticals, Inc. | 1 | $103 |
| Gilead Sciences, Inc. | 2 | $79 |
| GENZYME CORPORATION | 2 | $69 |
| JAZZ PHARMACEUTICALS INC. | 1 | $63 |
| Daiichi Sankyo Inc. | 2 | $51 |
| Boston Scientific Corporation | 1 | $38 |
| Merck Sharp & Dohme LLC | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
Products named: Zynyz, Vyloy, Trodelvy, SARCLISA, ZIIHERA, DATROWAY, SpyGlass Discover, KEYTRUDA.
Industry payments across CA — which companies pay providers there.
